For information on the clinical research behind SierraSil’s unique mineral complex, please visit the Joint Formula 14™ page.
Meriva® has also been studied extensively, the following is a brief compilation of the research associated with joint health and physical function:
The pain relieving properties of Meriva® were evaluated against that of Nimesulide and Acetaminophen.
Results: The analgesic effect of Meriva® was higher than that associated with acetaminophen while its gastric tolerability was significantly better at a 2 gram dose than that of Nimesulide.
Di Pierro, Francesco, Rapacoli et al. 2013. Comparative evaluation of the pain-relieving properties of a lecithinized formulation of curcumin (Meriva®), nimesulide, and acetaminophen. Journal of Pain Research. Vol 3. No 6: 201-05.
Safety and Efficacy Study
The long-term efficacy and safety of Meriva® were investigated in an 8-month study involving 100 patients suffering from Osteoarthritis.
Results: Meriva® was deemed “an effective and safe agent for the complementary management of osteoarthritis, leading to better disease control […] and overall improvement in quality of life.”
Belcaro, Gianni, Cesarone et al. 2010. Efficacy and Safety of Meriva®, a Curcumin-phosphatidylcholine Complex, during Extended Administration in Osteoarthritis Patients. Alternative Medicine Review. Vol 15. No 4: 337-43.
Systemic Availability Study
The oral bioavailability of Meriva® brand curcumin was studied alongside that of unformulated curcumin.
Results: Plasma level values were fivefold higher for Meriva® than the equivalent values seen with unformulated curcumin.
Marczylo, Timothy, Verschoyle et al. 2007. Comparison of systemic availability of curcumin with that of curcumin formulated with phosphatidylcholine. Cancer Chemother Pharmacol 60: 171-77.
Meriva® and the complementary management of bone and joint health
Meriva® was evaluated for its efficacy in 50 individuals affected by bone health challenge (X-ray diagnosis confirmation). The symptoms were evaluated by the WOMAC score; mobility was studied by walking performance on the treadmill and the overall inflammatory response function was assessed by measurements of C-reactive protein plasma concentration.
Results: The treadmill performance (10% inclination, 3 Km/h speed) showed an improvement of 201% of the initial walked distance at two months, and a further improvement (+44%) at three months from the beginning of the study. These positive results were complemented by secondary end-points, namely the decrease in supplemental therapy use (63% in the Meriva® group vs 12% in the treatment group) and the decrease in gastrointestinal complications (38% in Meriva® vs 15% in controls (p<0.05). Overall, the management costs in the Meriva® group decreased by 49% compared to a non significant 3% decrease for the control group.
Belcaro G., et al., Panminerva Medica, 2010, 52(2 Suppl 1): p. 55-62.
Meriva® for the maintenance of bone health
Meriva® was further confirmed in a larger and longer (8 months) investigation, that enrolled 100 participants and was, otherwise, methodologically similar to the previous one, including the dosage (1 g/day of Meriva®, corresponding to 200 mg curcumin/day in two separate administrations).
Results: The results showed that the Meriva® group enjoyed a statistically significant reduction in all primary clinical endpoints, the Western Ontario and McMaster Universities (WOMAC) score (decreased from 80.6 to 33.2), the Karnofsky Performance Scale (improved from 73.3 to 92.2), and the treadmill walking performance test. These results were complemented by the evaluation of a series of inflammatory response function markers wider than the one considered in the first study (interleukin [IL]-1b, IL-6, soluble CD40 ligand [sCD40L], soluble vascular cell adhesion molecule (sVCAM)-1, and erythrocyte sedimentation rate [ESR]) that also showed a marked reduction in the Meriva® treated group. Conversely, no significant variation was observed in the “best available treatment” control group.
Belcaro G., Cesarone M.R., Dugall M. et al., Altern Med Rev, 2010, 15(4): p. 337-44.
Meriva® and sports nutrition
In a randomized, double-blind, cross-over 3 arms controlled (supplement, placebo, control) study, 11 male recreational athletes consuming a low carbohydrate diet of 2.3 ± 0.2 g/kg/day underwent three double blind trials with curcumin supplementation, placebo supplementation, and no supplementation (control) to observe the response of serum interleukins (IL-6, IL1-RA, IL-10), cortisol, c-reactive protein (CRP), and subjective assessment of training stress after a challenge.
Results: The results shown that Meriva® at 500 mg/die is safe, is not doping, leads to measurable plasma concentrations in line with the published results, decreases the subjective perception of stress associated to exercise, and tends to decrease the production of IL-6, a marker of muscle fatigue associated to intense physical activity.
Sciberras, J.N., et al., J Int Soc Sports Nutr, 2015. 12(1): p. 5